CN111574594A - Preparation method of Bulevirtide - Google Patents
Preparation method of Bulevirtide Download PDFInfo
- Publication number
- CN111574594A CN111574594A CN202010457818.1A CN202010457818A CN111574594A CN 111574594 A CN111574594 A CN 111574594A CN 202010457818 A CN202010457818 A CN 202010457818A CN 111574594 A CN111574594 A CN 111574594A
- Authority
- CN
- China
- Prior art keywords
- bulevilide
- resin
- pro
- asn
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940061603 bulevirtide Drugs 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229920005989 resin Polymers 0.000 claims description 48
- 239000011347 resin Substances 0.000 claims description 48
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 239000012043 crude product Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 15
- 229920003180 amino resin Polymers 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- 238000011033 desalting Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108091006611 SLC10A1 Proteins 0.000 description 3
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 2-$l^{1}-oxidanyl-2-methylpropane Chemical compound CC(C)(C)[O] ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- -1 9-fluorenylmethoxycarbonyl group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091022863 bile acid binding Proteins 0.000 description 1
- 102000030904 bile acid binding Human genes 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940042040 innovative drug Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013316 polymer of intrinsic microporosity Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZTUXEFFFLOVXQE-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O ZTUXEFFFLOVXQE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OHSJPLSEQNCRLW-UHFFFAOYSA-N triphenylmethyl radical Chemical compound C1=CC=CC=C1[C](C=1C=CC=CC=1)C1=CC=CC=C1 OHSJPLSEQNCRLW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a preparation method of Bulevirtide, which adopts a special protective amino acid fragment of Myristonyn-Gly-Thr (tBu) -Asn (Trt) -Leu-Ser (tBu) -Val-Pro-Asn (Trt) -Pro-Leu-Gly-Phe-Phe-Pro-OH, shortens the preparation process period and improves the total yield of products in large-scale preparation.
Description
Technical Field
The invention belongs to the technical field of preparation methods of polypeptide medicaments, and particularly relates to a preparation method of Bulevirtide.
Background
A new generation of oral direct antiviral drugs achieves a cure for hepatitis C, but chronic Hepatitis B (HBV) infected patients currently require long-term or even lifetime treatment. There are about 20 billion HBV infected patients all over the world, but most of them are acute infections, and the immune system of the human body can rapidly play a role to completely eliminate the HBV. In addition, 3.8 million infected patients are chronic and the virus is hidden in tissues and organs and cannot be completely eliminated by the immune system and drugs.
Researchers have found that a protein called liver bile acid transporter (NTCP, sodium taurocholate cotransporter polypeptide) on the surface of hepatocytes can specifically interact with the key receptor binding domain of HBV envelope proteins, which are receptors required for HBV infection of host cells. Therefore, blocking NTCP would be expected to cure hepatitis B. Bulevirtide is a novel Firstinclass hepatitis B medicament targeting NTCP.
Active results of the Bulevirtide phase IIb study were reported by MyrPharma at the annual meeting of the European Association for liver disease. And (3) displaying data: after 48 weeks of Bulevilide in combination with PEG-IFN alpha, more than 50% of HBV/HDV co-infected patients had no detectable HDVRNA. Also, hepatitis B surface antigen (HBsAg) in some of the subjects reached undetectable levels. More importantly, the effect can still be continued after the medicine is stopped, which also means that the bullevirtide is expected to be an option for curing hepatitis B in the future.
Bulevirtide qualifies for orphan medication awarded by the FDA and EMA for the treatment of HDV infection, is under the priority drug (PRIME) program by EMA, and has received FDA ' breakthrough therapy ' approval and United kingdom drug and health product administration (MHRA) ' approval of highly desirable innovative drugs (PIMs).
Bulevilide has the following structure:
Myristony-Gly-Thr-Asn-Leu5-Ser-Val-Pro-Asn-Pro10-Leu-Gly-Phe-Phe-Pro15-Asp-His-Gln-Leu-Asp20-Pro-Ala-Phe-Gly-Ala25-Asn-Ser-Asn-Asn-Pro30-Asp-Trp-Asp-Phe-Asn35-Pro-Asn-Lys-Asp-His40-Trp-Pro-Glu-Ala-Asn45-Lys-Val-Gly-NH2
the invention provides an efficient Bulevirtide preparation method, which improves the purity and yield of high products so as to meet the medical application.
Disclosure of Invention
The invention provides a novel high-efficiency preparation method, which adopts special protected amino acid, shortens the preparation process period and improves the product purity and yield in a large-scale preparation method.
The invention provides a preparation method of Bulevirtide, which comprises the following steps: amino resin is adopted as starting resin, the Bulevilide is prepared by a solid-phase polypeptide synthesis method, Bulevilide resin is obtained by the polypeptide solid-phase synthesis method, a Bulevilide crude product is obtained by acidolysis of the Bulevilide resin, and finally the Bulevilide crude product is purified to obtain a Bulevilide pure product.
Wherein, in addition to other conventional protected amino acids, the following special protected amino acid fragments are used in the synthesis process of the Bulevilide multi-resin:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu-Ser(tBu)-Val-Pro-Asn(Trt)-Pro-Leu-Gly-Phe-Phe-Pro-OH
bulevilide peptide resin:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu5-Ser(tBu)-Val-Pro-Asn(Trt)-Pro10-Leu-Gly-Phe-Phe-Pro15-Asp(OtBu)-His(Trt)-Gln(Trt)-Leu-Asp(OtBu)20-Pro-Ala-Phe-Gly-Ala25-Asn(Trt)-Ser(tBu)-Asn(Trt)-Asn(Trt)-Pro30-Asp(OtBu)-Trp(Boc)-Asp(OtBu)-Phe-Asn(Trt)35-Pro-Asn(Trt)-Lys(Boc)-Asp(OtBu)-His(Trt)40-Trp(Boc)-Pro-Glu(OtBu)-Ala-Asn(Trt)45-Lys (Boc) -Val-Gly-amino resin
In the preparation method of Bulevirtide, the amino resin has an amino substitution value of 0.2-0.8 mmol/g resin, and the preferable substitution value is 0.3-0.5 mmol/g resin.
In the preparation method of Bulevirtide, the amino resin is one of Rink MBHA resin, Rink Amide resin or Rink Amide AM resin, and Rink Amide MBHA resin is preferred.
In the Bulevirtide preparation method, the dosage of the Fmoc-protected amino acid or the protected amino acid fragment is 1.2-6 times of the total mole number of the charged resin; preferably 2.5 to 3.5 times.
In a preferred embodiment of the invention, the Bulevilide resin is subjected to acidolysis and resin and side chain protecting groups are removed simultaneously to obtain a Bulevilide element linear peptide crude product.
Further, an acidolysis agent adopted in acidolysis of the Bulevirtide resin is a mixed solvent of trifluoroacetic acid (TFA), 1, 2-Ethanedithiol (EDT) and water, and the mixture ratio of the mixed solvent is as follows: the TFA ratio is 80-95% (V/V), the EDT ratio is 1-10% (V/V), and the balance is water. The preferred formulation is 89-91% TFA, 4-6% EDT, and the balance water. Preferably, the mixture ratio is 90%, EDT 5% and the balance of water.
The dosage of the acidolysis agent is 4-15 ml of acidolysis agent per gram of Bulevilide resin, and preferably 9-11 ml of acidolysis agent per gram of Bulevilide resin. The time for cracking by using the acidolysis agent is 1-5 hours, preferably 2 hours at room temperature.
Further, the Bulevilide crude product is purified by high performance liquid chromatography and freeze-dried to obtain a Bulevilide pure product, and the specific method comprises the following steps:
adding water into the Bulevitide crude product, stirring, adjusting the pH value to 8.0 by using ammonia water until the Bulevitide crude product is completely dissolved, filtering the solution by using a 0.45-micrometer mixed microporous filter membrane, and purifying for later use;
purifying by high performance liquid chromatography, wherein the purification is carried out by using reversed phase C18 with chromatographic packing of 10 mu m, alternately purifying by using two mobile phase systems, the first mobile phase system is 0.1% TFA/water solution-0.1% TFA/acetonitrile solution, the second mobile phase system is 50mmol ammonium acetate/water solution-acetonitrile, the flow rate of a chromatographic column of 77mm 250mm is 90mL/min, eluting by using a gradient system, circularly injecting and purifying, sampling a crude product solution into the chromatographic column, starting mobile phase elution, collecting a main peak to evaporate acetonitrile, filtering by using a 0.45 mu m filter membrane to obtain a Bulevitide purified intermediate concentrated solution, adjusting the pH to 8.0, and preparing for desalting.
Desalting by high performance liquid chromatography with mobile phase system of water solution-acetonitrile, purification with reversed phase C18 with chromatographic packing of 10 μm, and chromatographic column flow rate of 77mm × 250mm of 90 mL/min; adopting a gradient elution and circulating sample loading method, loading a sample into a chromatographic column, starting mobile phase elution, collecting a spectrum, observing the change of the absorbance, collecting a main desalting peak, detecting the purity by using an analytical liquid phase, combining the main desalting peak solutions, concentrating under reduced pressure to obtain a Bulevirtide aqueous solution, and freeze-drying to obtain a Bulevirtide pure product.
The method of the invention directly uses the following special protected amino acids:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu-Ser(tBu)-Val-Pro-Asn(Trt)-Pro-Leu-Gly-Phe-Phe-Pro-OH
shortens the production period, greatly improves the purity of the crude product, improves the product yield, and has wide practical value and application prospect.
Detailed Description
The invention discloses a method for synthesizing Bulevirtide, which can be realized by appropriately improving process parameters by referring to the content in the text. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the methods described herein, as well as appropriate variations and combinations of the methods described herein, may be made and the techniques of the present invention employed without departing from the spirit and scope of the invention.
In the specific embodiment of the present invention, the Chinese meanings corresponding to the English abbreviations used in the application documents are shown in Table 1.
TABLE 1
| English abbreviation | Name of Chinese | English abbreviation | Name of Chinese |
| Fmoc | 9-fluorenylmethoxycarbonyl group | OtBu | Tert-butoxy radical |
| tBu | Tert-butyl radical | Boc | Boc-acyl |
| Trt | Trityl radical | Leu | Leucine |
| Ser | Serine | Phe | Phenylalanine |
| Glu | Glutamic acid | Thr | Threonine |
| Trp | Tryptophan | Arg | Arginine |
| Asp | Aspartic acid | Gln | Glutamine |
| Ala | Alanine | Ile | Isoleucine |
| Tyr | Tyrosine | His | Histidine |
| Gly | Glycine | Lys | Lysine |
| Val | Valine | Myristic acid | Myristic acid |
The invention is further illustrated by the following examples.
Example 1 Synthesis of Bulevirtide peptide resin by fragment ligation
Bulevilide peptide resin:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu5-Ser(tBu)-Val-Pro-Asn(Trt)-Pro10-Leu-Gly-Phe-Phe-Pro15-Asp(OtBu)-His(Trt)-Gln(Trt)-Leu-Asp(OtBu)20-Pro-Ala-Phe-Gly-Ala25-Asn(Trt)-Ser(tBu)-Asn(Trt)-Asn(Trt)-Pro30-Asp(OtBu)-Trp(Boc)-Asp(OtBu)-Phe-Asn(Trt)35-Pro-Asn(Trt)-Lys(Boc)-Asp(OtBu)-His(Trt)40-Trp(Boc)-Pro-Glu(OtBu)-Ala-Asn(Trt)45-Lys (Boc) -Val-Gly-amino resin
Rink Amide MBHA resin is used as initial resin, and is sequentially coupled with protected amino acids shown in table 2 through Fmoc protection removal and coupling reaction to prepare Bulevitide peptide resin. The protection fragments used in this example were: Myristony-Gly-Thr (tBu) -Asn (Trt) -Leu-Ser (tBu) -Val-Pro-Asn (Trt) -Pro-Leu-Gly-Phe-Phe-Pro-OH
TABLE 2
1. Introduction of the 1 st protected amino acid
Dissolving 0.03mol of the 1 st protected amino acid and 0.03mol of HOBt in a proper amount of DMF; and adding 0.03mol DIC slowly into the protected amino acid DMF solution under stirring, and reacting for 30 minutes under stirring at room temperature to obtain an activated protected amino acid solution for later use.
0.01mol of Fmoc-Gly-resin (substitution value about 0.5mmol/g) was taken, deprotected with 20% PIP/DMF solution for 25 min, washed and filtered to give Fmoc-removed resin.
And adding the activated 1 st protected amino acid solution into the Fmoc-removed resin, performing coupling reaction for 120-300 minutes, and filtering and washing to obtain the resin containing 1 protected amino acid.
2. Inoculating 2-34 protected amino acids or fragments
And sequentially inoculating the corresponding 2 nd to 34 th protected amino acids or fragments by adopting the same method to obtain the Bulevirtide peptide resin.
Example 2 Synthesis of Bulevirtide peptide resin Using a conventional one-by-one grafting method
Bulevilide peptide resin:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu5-Ser(tBu)-Val-Pro-Asn(Trt)-Pro10-Leu-Gly-Phe-Phe-Pro15-Asp(OtBu)-His(Trt)-Gln(Trt)-Leu-Asp(OtBu)20-Pro-Ala-Phe-Gly-Ala25-Asn(Trt)-Ser(tBu)-Asn(Trt)-Asn(Trt)-Pro30-Asp(OtBu)-Trp(Boc)-Asp(OtBu)-Phe-Asn(Trt)35-Pro-Asn(Trt)-Lys(Boc)-Asp(OtBu)-His(Trt)40-Trp(Boc)-Pro-Glu(OtBu)-Ala-Asn(Trt)45-Lys (Boc) -Val-Gly-amino resin
Rink Amide MBHA resin is used as initial resin, and is sequentially coupled with protected amino acids shown in table 2 through Fmoc protection removal and coupling reaction to prepare Bulevitide peptide resin.
TABLE 3
1. Introduction of the 1 st protected amino acid
Dissolving 0.03mol of the 1 st protected amino acid and 0.03mol of HOBt in a proper amount of DMF; and adding 0.03mol DIC slowly into the protected amino acid DMF solution under stirring, and reacting for 30 minutes under stirring at room temperature to obtain an activated protected amino acid solution for later use.
0.01mol of Fmoc-Gly-resin (substitution value about 0.5mmol/g) was taken, deprotected with 20% PIP/DMF solution for 25 min, washed and filtered to give Fmoc-removed resin.
And adding the activated 1 st protected amino acid solution into the Fmoc-removed resin, performing coupling reaction for 120-300 minutes, and filtering and washing to obtain the resin containing 1 protected amino acid.
2. Inoculating 2-48 protected amino acids or fatty acids
And sequentially inoculating the corresponding 2 nd to 48 th protected amino acids or fatty acids by adopting the same method to obtain the Bulevirtide peptide resin.
EXAMPLE 3 preparation of crude Bulevilide
Taking Bulevilide peptide resin prepared in example 1, adding a cleavage reagent (10 mL/g resin of the cleavage reagent) with the volume ratio of TFA, water and EDT (95: 5), uniformly stirring, stirring at room temperature for reaction for 3 hours, filtering a reaction mixture by using a sand core funnel, collecting a filtrate, washing the resin with a small amount of TFA for 3 times, combining the filtrates, concentrating under reduced pressure, adding anhydrous ether for precipitation, washing the precipitate with anhydrous ether for 3 times, and drying under reduced pressure at 35-45 ℃ to obtain a Bulevilide crude product with the purity of 67.3%.
EXAMPLE 4 preparation of crude Bulevilide
Taking Bulevilide peptide resin prepared in example 2, adding a cleavage reagent (10 mL/g resin of the cleavage reagent) with the volume ratio of TFA, water and EDT (95: 5), uniformly stirring, stirring at room temperature for reaction for 3 hours, filtering a reaction mixture by using a sand core funnel, collecting a filtrate, washing the resin with a small amount of TFA for 3 times, combining the filtrates, concentrating under reduced pressure, adding anhydrous ether for precipitation, washing the precipitate with anhydrous ether for 3 times, and drying under reduced pressure at 35-45 ℃ to obtain a Bulevilide crude product with the purity of 45.7%.
EXAMPLE 5 purification of crude Bulevilide
Taking the Bulevilide crude product prepared in the embodiment 3, adding water, stirring, adjusting the pH to 8.0 by using ammonia water until the Bulevilide crude product is completely dissolved, filtering the solution by using a 0.45-micron mixed microporous filter membrane, and purifying for later use;
purification was performed by high performance liquid chromatography using reverse phase C18 with 10 μm chromatography packing and alternating purification with two mobile phase systems, the first being 0.1% TFA/water-0.1% TFA/acetonitrile and the second being 50mmol ammonium acetate/water-acetonitrile. The flow rate of a chromatographic column of 77mm x 250mm is 90mL/min, a gradient system is adopted for elution, circulation sample injection purification is carried out, a crude product solution is taken to be loaded in the chromatographic column, mobile phase elution is started, a main peak is collected, acetonitrile is evaporated, and then a 0.45-micrometer filter membrane is used for filtration, so as to obtain a Bulevirtide purified intermediate concentrated solution, the acidity is adjusted to 8.0, and the Bulevirtide purified intermediate concentrated solution is prepared for desalination;
desalting by high performance liquid chromatography with mobile phase system of water solution-acetonitrile, purification with reversed phase C18 with chromatographic packing of 10 μm, and chromatographic column flow rate of 77mm × 250mm of 90 mL/min; the method comprises the steps of adopting a gradient elution and circulation loading method, loading a sample into a chromatographic column, starting mobile phase elution, collecting a map, observing the change of absorbance, collecting a desalted main peak, detecting the purity by using an analytical liquid phase, combining desalted main peak solutions, concentrating under reduced pressure to obtain a Bulevilide aqueous solution, and freeze-drying to obtain a Bulevilide pure product 13.7g, wherein the purity is 99.1%, the maximum single impurity content is 0.13%, the total yield is 25.4%, and the molecular weight is 5399.2 (100% M + H).
EXAMPLE 6 purification of crude Bulevilide
Taking the Bulevilide crude product prepared in the embodiment 4, adding water, stirring, adjusting the pH to 8.0 by using ammonia water until the Bulevilide crude product is completely dissolved, filtering the solution by using a 0.45-micron mixed microporous filter membrane, and purifying for later use;
purification was performed by high performance liquid chromatography using reverse phase C18 with 10 μm chromatography packing and alternating purification with two mobile phase systems, the first being 0.1% TFA/water-0.1% TFA/acetonitrile and the second being 50mmol ammonium acetate/water-acetonitrile. The flow rate of a chromatographic column of 77mm x 250mm is 90mL/min, a gradient system is adopted for elution, circulation sample injection purification is carried out, a crude product solution is taken to be loaded in the chromatographic column, mobile phase elution is started, a main peak is collected, acetonitrile is evaporated, and then a 0.45-micrometer filter membrane is used for filtration, so as to obtain a Bulevirtide purified intermediate concentrated solution, the acidity is adjusted to 8.0, and the Bulevirtide purified intermediate concentrated solution is prepared for desalination;
desalting by high performance liquid chromatography with mobile phase system of water solution-acetonitrile, purification with reversed phase C18 with chromatographic packing of 10 μm, and chromatographic column flow rate of 77mm × 250mm of 90 mL/min; the method comprises the steps of adopting a gradient elution and circulation loading method, loading a sample into a chromatographic column, starting mobile phase elution, collecting a map, observing the change of absorbance, collecting a desalted main peak, detecting the purity by using an analytical liquid phase, combining desalted main peak solutions, concentrating under reduced pressure to obtain a Bulevilide aqueous solution, and freeze-drying to obtain a Bulevilide pure product with the purity of 98.2 percent, the maximum single impurity content of 0.39 percent, the total yield of 12.8 percent and the molecular weight of 5399.0(100 percent M + H).
The above examples show that the purity of the product obtained by the method provided by the invention is more than 99.0%, and the total yield of the product is 25.4%, while the total yield of the conventional one-by-one access method is only 12.8%. The method obviously improves the purity of the crude product and the total yield of the product, and has wide practical value and application prospect.
Claims (6)
1. A method of preparing bulevitide, comprising: amino resin is adopted as initial resin, Bulevilide peptide resin is prepared by a solid-phase polypeptide synthesis method, Bulevilide peptide resin is subjected to acidolysis to obtain a Bulevilide crude product, and finally, the Bulevilide crude product is purified and freeze-dried to obtain a Bulevilide pure product:
Myristony-Gly-Thr-Asn-Leu5-Ser-Val-Pro-Asn-Pro10-Leu-Gly-
Phe-Phe-Pro15-Asp-His-Gln-Leu-Asp20-Pro-Ala-Phe-Gly-Ala25-
Asn-Ser-Asn-Asn-Pro30-Asp-Trp-Asp-Phe-Asn35-Pro-Asn-Lys-
Asp-His40-Trp-Pro-Glu-Ala-Asn45-Lys-Val-Gly-NH2
2. the method for producing Bulevilide as defined in claim 1, wherein: when Myristic acid at the 1 st position to Pro at the 15 th position are accessed together, the corresponding protected amino acid fragments are as follows:
Myristony-Gly-Thr(tBu)-Asn(Trt)-Leu-Ser(tBu)-Val-Pro-Asn(Trt)-Pro-Leu-Gly-Phe-
Phe-Pro-OH
3. the Bulevirtide preparation method according to claim 1, wherein the amino resin has an amino substitution value of 0.2 to 0.8mmol/g resin, preferably a substitution value of 0.3 to 0.5mmol/g resin.
4. The method for preparing Bulevilide as claimed in claim 1, wherein the amino resin is one of Rink MBHA resin, Rink Amide resin or Rink Amide AM resin, preferably Rink Amide MBHA resin.
5. The method for producing Bulevilide according to any one of claims 1 to 4, wherein: and carrying out acidolysis on the Bulevilide peptide resin, and simultaneously removing the resin and a side chain protecting group to obtain a Bulevilide crude product.
6. The method for producing Bulevilide as defined in claim 1, wherein: the crude Bulevilide product is purified by high performance liquid chromatography and freeze-dried to obtain a pure Bulevilide product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010457818.1A CN111574594A (en) | 2020-05-26 | 2020-05-26 | Preparation method of Bulevirtide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010457818.1A CN111574594A (en) | 2020-05-26 | 2020-05-26 | Preparation method of Bulevirtide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111574594A true CN111574594A (en) | 2020-08-25 |
Family
ID=72121441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010457818.1A Pending CN111574594A (en) | 2020-05-26 | 2020-05-26 | Preparation method of Bulevirtide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111574594A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104781274A (en) * | 2012-11-12 | 2015-07-15 | 海德堡吕布莱希特-卡尔斯大学 | Lipopetides for use in treating liver diseases and cardiovascular diseases |
| CN109354623A (en) * | 2012-04-25 | 2019-02-19 | 华辉安健（北京）生物科技有限公司 | The composition and related application of Hepaitis B virus functional receptor |
| CN110818790A (en) * | 2019-10-31 | 2020-02-21 | 成都圣诺生物制药有限公司 | Preparation method of temeprelin |
-
2020
- 2020-05-26 CN CN202010457818.1A patent/CN111574594A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109354623A (en) * | 2012-04-25 | 2019-02-19 | 华辉安健（北京）生物科技有限公司 | The composition and related application of Hepaitis B virus functional receptor |
| CN104781274A (en) * | 2012-11-12 | 2015-07-15 | 海德堡吕布莱希特-卡尔斯大学 | Lipopetides for use in treating liver diseases and cardiovascular diseases |
| CN110818790A (en) * | 2019-10-31 | 2020-02-21 | 成都圣诺生物制药有限公司 | Preparation method of temeprelin |
Non-Patent Citations (3)
| Title |
|---|
| ALEXA SCHIECK等: "Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor" * |
| DAVID CRICH: "Epimerization-Free Block Synthesis of Peptides from Thioacids and Amines with the Sanger and Mukaiyama Reagents" * |
| 徐在超等: "乙型肝炎抗病毒药物研究进展" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107960079B (en) | Synthesis method of low-racemization impurity liraglutide | |
| Tatemoto et al. | Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin | |
| CA2091873C (en) | Parathyroid hormone derivatives | |
| CN110903355A (en) | Preparation method of Tirzepatide | |
| JPH03504013A (en) | Peptide with T cell helper activity | |
| CN110818790A (en) | Preparation method of temeprelin | |
| US9394341B2 (en) | Eptifibatide preparation method | |
| CN104788546A (en) | Preparation method of linear peptides containing 24 amino acid residues | |
| CN104098688A (en) | Method for synthesizing thymalfasin | |
| HUT61579A (en) | Process for producing polypeptides and pharmaceutical compositions with anti-hiv activity, comprising same as active ingredient | |
| CN104844706A (en) | Method for synthesizing lixisenatide | |
| CN110759972A (en) | Preparation method of atosiban | |
| CN111303245A (en) | Anti-syncytial virus membrane fusion inhibitor | |
| CN104817638A (en) | Method for synthesizing teduglutide | |
| CN109306366B (en) | Method for synthesizing PT141 | |
| CN110054679B (en) | Method for synthesizing Abalopratide | |
| CN107778351B (en) | Method for synthesizing octreotide by all-solid-phase method | |
| CN114075275A (en) | Long-acting insulin analogue | |
| Albericio et al. | Solid phase synthesis and HPLC purification of the protected 1-12 sequence of apamin for rapid synthesis of apamin analogues differing in the C-terminal region | |
| CN111217901A (en) | Preparation method of Somalutide | |
| CN111560061A (en) | Preparation method of Gelpaglutide | |
| CN111574594A (en) | Preparation method of Bulevirtide | |
| CN111518192A (en) | Preparation method of Apraglutide | |
| JPS58140024A (en) | Purification method of secretin | |
| CN111560062A (en) | Preparation method of Elisiglilutide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200825 |